IL6 and Low back pain: To address these limitations, future research must focus on large-scale, multi-center trials to validate efficacy, the development of standardized functional biomarkers (beyond CRP/IL-6) specifically sensitive to microbiome-mediated healthspan changes, and the utilization of AI/machine learning to predict individual responsiveness to personalized LBP or postbiotic therapy.